肺癌患者红细胞CD35、CD44s、CD58测定及其意义

王恩举; 潘立民; 张伊莉; 李莹; 穆新林; 陈余清

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肺癌患者红细胞CD35、CD44s、CD58测定及其意义

王恩举 , 潘立民 , 张伊莉 , 李莹 , 穆新林 , 陈余清

文章导航 > 蚌埠医学院学报 > 2004, 29 > 3: (241-243)

引用本文:

Citation:

肺癌患者红细胞CD35、CD44s、CD58测定及其意义

1. 蚌埠铁路中心医院(蚌埠医学院第二附属医院)内科, 安徽蚌埠 233040;
2. 蚌埠医学院附属医院肺科, 安徽蚌埠 233004

作者简介: 王恩举(1959-),男,安徽明光人,副主任医师。

中图分类号: R734.2

Significance of quantitative assay of CD35、CD44s and CD58 expressed on erythrocytes in patients with lung cancer

Department of Internal Medicine, Bengbu Railway Central Hospital, Anhui 233040, China
CLC number: R734.2

摘要: 目的: 探讨肺癌患者红细胞CD35、CD44s、CD58在不同病理类型、不同分期及化疗前后分子的数量变化。方法: 参照王海滨方法,将经过处理的定量红细胞悬液,移入V型板中,依次加入CD35、CD44s、CD58单克隆抗体。进行细胞酶免疫分析。取上清液,在酶标仪405 nm读取其吸光度A值;减去对照孔A值为标本的的测定值。结果: 不同病理类型的肺癌红细胞CD35、CD44s和CD58除差分化癌外,均较正常组降低(P<0。05~P<0。01)。但各病理类型之间红细胞CD35、CD44s、CD58比较,差异均无显著性(P>0。05)。Ⅲ、Ⅳ期肺癌组红细胞CD35和CD44s较Ⅰ、Ⅱ期肺癌组降低(P<0。05)。化疗组肺癌红细胞CD35较非化疗组降低(P<0。05),CD44s和CD58两组比较,差异均无显著性(P>0。05)。结论: 肺癌患者红细胞CD35、CD44s、CD58较正常人降低,且随着病情的进展红细胞免疫功能进一步下降,表明红细胞CD35、CD44s、CD58分子数量的变化与肿瘤的转移和恶化程度有关。这种关系的紊乱可能对肺癌的发生、发展、预后产生重要的影响。
- 肺肿瘤 /
- 红细胞膜免疫分子 /
- CD35 /
- CD44s /
- CD58
Abstract: Objective: To investigate the relationship between quantitative molecule expresssion of CD35,CD44s and CD58 on erythrocytes and types of pathology,stages and before and after chemical treatment in lung cancer.Methods: Glutaraldehyde-fixed red blood cells were analyzed in ‘V’ microtitre plates,mouse monoclonal antihuman CD35,CD44s and CD58 were added in order.After immunoenzymic reaction process in the plates,the red bloodcell supernatant was transferred to a clean microtitre plate and read at 405nm (A405).Results: Except poorly differentiated lung cancer,CD35,CD44s and CD58 expressed were significantly lower on erythrocytes in various pathologic types in lung cancer groups than in control group.The difference was significant(P<0.05 and P<0.01).The difference was not significant in CD35,CD44s and CD58 expressed(P<0.05) on erythrocytes in various pathologic types of lung cancer (P>0.05).It showed that quantitative molecule expression of CD35,CD44s and CD58 in the patients with lung cancer in Ⅲ and Ⅳ stages were significantly lower than that in Ⅰ and Ⅱ stages(P<0.05).Compared with the patients with lung cancer before chemical treatment,expression of CD35 was significantly lower in the patients with lung cancer after chemical treatment.There was no significant difference between CD44s and CD58 molecule expressions(P>0.05).Conclusions: Our data suggest that quantitative molecule expression of CD35,CD44s and CD58 on erythrocytes in the patients with lung cancer is lower than normal and the erythrocytes immuno function descends with the aggravation of the disease.Furthermore,this data displays that change of CD35,CD44s and CD58 quantities expression on erythrocytes is associated with metastasis and deterioration of the tumor in the patients with lung cancer,which may be of importantce to the development and prognosis of lung cancer.
- lung neoplasms /
- erythrocytes membrane immune molecule /
- CD35 /
- CD44s /
- CD58

[1]	李莹 , 张伊莉 , 潘立民 , 王恩举 , 卞建军 , 王海滨 . 慢性肾功能衰竭红细胞CD35、CD44s、CD58分子的变化及意义. 蚌埠医学院学报, 2004, 29(2): 134-135.
[2]	杨兵 , 潘莹 , 蔡韶芳 , 杜均祥 , 龚五星 . CD4⁺ CD25⁺调节性T细胞在肺癌中的表达及其临床意义. 蚌埠医学院学报, 2015, 40(5): 627-628. doi: 10.13898/j.cnki.issn.1000-2200.2015.05.022
[3]	芮艳 , 胡丹凤 , 黄礼年 . 达肝素钠抑制人肺腺癌细胞增殖作用的实验观察. 蚌埠医学院学报, 2014, 38(3): 284-287.
[4]	刘戈 , 唐震 , 刘学刚 , 施超 , 王祖义 , 刘以尧 , 段贵新 . 肺鳞状细胞癌251例淋巴结转移规律分析. 蚌埠医学院学报, 2015, 40(2): 155-158. doi: 10.13898/j.cnki.issn.1000-2200.2015.02.005
[5]	刘黎明 , 张永 , 胡俊峰 . c-myc RNA干扰增强肺腺癌细胞对吉西他滨的敏感性. 蚌埠医学院学报, 2009, 34(9): 765-768.
[6]	孙悝 , 吕小艳 , 刘小云 , 程霞 , 金齐力 . 呼吸系统炎症与肿瘤病人血清细胞质胸苷激酶1水平比较. 蚌埠医学院学报, 2017, 42(6): 814-815,818. doi: 10.13898/j.cnki.issn.1000-2200.2017.06.037
[7]	杨玲 . 多西他赛为主方案治疗非小细胞肺癌35例分析. 蚌埠医学院学报, 2008, 33(3): 301-302.
[8]	李想 , 陈艾琪 , 曹胜男 , 李伟 , 唐聪聪 , 杜小萌 , 马宜传 . 双能量CT虚拟平扫结合影像组学在诊断肺鳞状细胞癌与肺腺癌中的价值. 蚌埠医学院学报, 2023, 48(11): 1562-1565. doi: 10.13898/j.cnki.issn.1000-2200.2023.11.018
[9]	孙谦 , 宣爱丽 , 汪庚明 , 周咏春 , 徐洪波 , 何泽来 , 周燕 , 周育夫 , 江浩 . 全反式维A酸对肺腺癌H1299细胞放射敏感性研究. 蚌埠医学院学报, 2021, 46(3): 281-285. doi: 10.13898/j.cnki.issn.1000-2200.2021.03.001
[10]	陶新全 , 王明明 . ¹⁸氟-脱氧葡萄糖诱导Lewis肺癌细胞凋亡的实验研究. 蚌埠医学院学报, 2009, 34(10): 865-867.
[11]	徐晓婉 , 唐淑慧 , 张锚 , 管诗佳 . 非小细胞肺癌病人常见免疫治疗不良反应的影响因素分析. 蚌埠医学院学报, 2022, 47(8): 1096-1101. doi: 10.13898/j.cnki.issn.1000-2200.2022.08.025
[12]	张生义 , 张己为 , 张旭峰 , 张逸 , 许斌斌 , 左顺庆 . 华蟾素对非小细胞肺癌细胞株A549细胞增殖及PTEN/AKT/mTOR信号通路表达的影响. 蚌埠医学院学报, 2020, 45(9): 1159-1162. doi: 10.13898/j.cnki.issn.1000-2200.2020.09.004
[13]	夏雪梅 , 陈余清 , 蔡映云 , 李殿明 , 胡俊锋 , 黄礼年 . Survivin反义寡核苷酸诱导肺癌细胞株凋亡的研究. 蚌埠医学院学报, 2005, 30(1): 4-8.
[14]	胡俊锋 , 陈余清 , 李殿民 , 夏雪梅 , 邓静 , 黄礼年 . 全反式维A酸诱导肺癌细胞株凋亡的研究. 蚌埠医学院学报, 2005, 30(2): 104-107.
[15]	李伟 , 陈余清 , 周继红 , 李殿明 , 徐凤珍 , 夏雪梅 . Survivin反义寡核苷酸经线粒体途径诱导肺癌细胞凋亡研究. 蚌埠医学院学报, 2005, 30(6): 482-486.
[16]	王同 , 梅晓冬 , 徐晓玲 , 李秀 , 高圣堂 , 李庆 . 利福霉素逆转多药耐药细胞系A₅₄₉/ADM的实验研究. 蚌埠医学院学报, 2007, 32(6): 640-642.
[17]	王洪亚 , 韩啸 , 王子安 . 紫杉醇联合顺铂治疗中晚期非小细胞肺癌34例分析. 蚌埠医学院学报, 2009, 34(8): 682-684.
[18]	金建华 , 王芳 , 陆文斌 , 赵宏祥 , 倪晓谦 . 多西紫杉醇联合顺铂治疗晚期非小细胞肺癌临床观察. 蚌埠医学院学报, 2005, 30(6): 513-515.
[19]	王荣俊 , 童斯浩 . 姜黄素联合紫杉醇对肺癌细胞PC9凋亡的影响. 蚌埠医学院学报, 2016, 41(12): 1549-1551. doi: 10.13898/j.cnki.issn.1000-2200.2016.12.003
[20]	吴迪 , 沈兆坤 , 陈聪 . 干扰LncRNA LRRC75A-AS1抑制肺癌细胞发生发展研究. 蚌埠医学院学报, 2022, 47(4): 442-446. doi: 10.13898/j.cnki.issn.1000-2200.2022.04.005

点击查看大图

计量

文章访问数: 3663
HTML全文浏览量: 310
PDF下载量: 9
被引次数: 0

肺癌患者红细胞CD35、CD44s、CD58测定及其意义

作者简介: 王恩举(1959-),男,安徽明光人,副主任医师。

1. 蚌埠铁路中心医院(蚌埠医学院第二附属医院)内科, 安徽蚌埠 233040;
2. 蚌埠医学院附属医院肺科, 安徽蚌埠 233004

收稿日期: 2004-01-08

关键词:

摘要: 目的: 探讨肺癌患者红细胞CD35、CD44s、CD58在不同病理类型、不同分期及化疗前后分子的数量变化。方法: 参照王海滨方法,将经过处理的定量红细胞悬液,移入V型板中,依次加入CD35、CD44s、CD58单克隆抗体。进行细胞酶免疫分析。取上清液,在酶标仪405 nm读取其吸光度A值;减去对照孔A值为标本的的测定值。结果: 不同病理类型的肺癌红细胞CD35、CD44s和CD58除差分化癌外,均较正常组降低(P<0。05~P<0。01)。但各病理类型之间红细胞CD35、CD44s、CD58比较,差异均无显著性(P>0。05)。Ⅲ、Ⅳ期肺癌组红细胞CD35和CD44s较Ⅰ、Ⅱ期肺癌组降低(P<0。05)。化疗组肺癌红细胞CD35较非化疗组降低(P<0。05),CD44s和CD58两组比较,差异均无显著性(P>0。05)。结论: 肺癌患者红细胞CD35、CD44s、CD58较正常人降低,且随着病情的进展红细胞免疫功能进一步下降,表明红细胞CD35、CD44s、CD58分子数量的变化与肿瘤的转移和恶化程度有关。这种关系的紊乱可能对肺癌的发生、发展、预后产生重要的影响。

English Abstract

Significance of quantitative assay of CD35、CD44s and CD58 expressed on erythrocytes in patients with lung cancer

Department of Internal Medicine, Bengbu Railway Central Hospital, Anhui 233040, China

Received Date: 2004-01-08

Abstract: Objective: To investigate the relationship between quantitative molecule expresssion of CD35,CD44s and CD58 on erythrocytes and types of pathology,stages and before and after chemical treatment in lung cancer.Methods: Glutaraldehyde-fixed red blood cells were analyzed in ‘V’ microtitre plates,mouse monoclonal antihuman CD35,CD44s and CD58 were added in order.After immunoenzymic reaction process in the plates,the red bloodcell supernatant was transferred to a clean microtitre plate and read at 405nm (A405).Results: Except poorly differentiated lung cancer,CD35,CD44s and CD58 expressed were significantly lower on erythrocytes in various pathologic types in lung cancer groups than in control group.The difference was significant(P<0.05 and P<0.01).The difference was not significant in CD35,CD44s and CD58 expressed(P<0.05) on erythrocytes in various pathologic types of lung cancer (P>0.05).It showed that quantitative molecule expression of CD35,CD44s and CD58 in the patients with lung cancer in Ⅲ and Ⅳ stages were significantly lower than that in Ⅰ and Ⅱ stages(P<0.05).Compared with the patients with lung cancer before chemical treatment,expression of CD35 was significantly lower in the patients with lung cancer after chemical treatment.There was no significant difference between CD44s and CD58 molecule expressions(P>0.05).Conclusions: Our data suggest that quantitative molecule expression of CD35,CD44s and CD58 on erythrocytes in the patients with lung cancer is lower than normal and the erythrocytes immuno function descends with the aggravation of the disease.Furthermore,this data displays that change of CD35,CD44s and CD58 quantities expression on erythrocytes is associated with metastasis and deterioration of the tumor in the patients with lung cancer,which may be of importantce to the development and prognosis of lung cancer.